SandboxAQ Showcases Federated AI Focus in Drug Discovery Collaboration Webinar

A LinkedIn post from SandboxAQ highlights an upcoming March 24 webinar on the role of federated AI in improving binding affinity models for early drug discovery. The post suggests that while structure prediction is increasingly mature, accurately gauging binding strength and selectivity remains a critical bottleneck for biologically meaningful candidates.

According to the post, SandboxAQ’s VP of Drug Discovery, Andrea Bortolato, PhD, will join participants from Johnson & Johnson Innovative Medicines and Rhino Federated Computing to discuss cross-industry collaboration without sharing proprietary data. For investors, this emphasis on federated AI and secure data collaboration may indicate SandboxAQ’s intent to position its technology as enabling infrastructure for pharma and biotech R&D, potentially expanding its addressable market and deepening strategic ties with larger industry players.